AR and essential thrombocythemia: Hence, a better approach in targeting various AR populations in ET-R BCa, as the unmodified (active) and SUMO-modified (hyperactive) forms of AR, could be achieved by combining AR-targeted therapies (as Enz or Bic) with SUMOylation inhibitors (as GA).